These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 8997477

  • 1. Fish oil therapy in IgA nephropathy.
    Fung SM, Ferrill MJ, Norton LL.
    Ann Pharmacother; 1997 Jan; 31(1):112-5. PubMed ID: 8997477
    [Abstract] [Full Text] [Related]

  • 2. Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy.
    Parinyasiri U, Ong-Ajyooth L, Parichatikanond P, Ong-Ajyooth S, Liammongkolkul S, Kanyog S.
    J Med Assoc Thai; 2004 Feb; 87(2):143-9. PubMed ID: 15061297
    [Abstract] [Full Text] [Related]

  • 3. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
    [Abstract] [Full Text] [Related]

  • 4. Advances in treatment: immunoglobulin A nephropathy.
    Hogg RJ, Waldo B.
    Semin Nephrol; 1996 Nov; 16(6):511-6. PubMed ID: 9125795
    [Abstract] [Full Text] [Related]

  • 5. The treatment of IgA nephropathy: status at the end of the millenium.
    Glassock RJ.
    J Nephrol; 1999 Nov; 12(5):288-96. PubMed ID: 10630691
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study.
    Manno C, Strippoli GF, D'Altri C, Torres D, Rossini M, Schena FP.
    Am J Kidney Dis; 2007 Jun; 49(6):763-75. PubMed ID: 17533019
    [Abstract] [Full Text] [Related]

  • 9. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
    Pozzi C, Del Vecchio L, Locatelli F.
    G Ital Nefrol; 2002 Jun; 19(5):523-8. PubMed ID: 12439840
    [Abstract] [Full Text] [Related]

  • 10. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 11. [Long-term administration of cyclosporine A in patients with IgA nephropathy].
    Chábová V, Tesar V, Zabka J, Rychlík I, Merta M, Jirsa M, Stejskalová A, Stejskal J.
    Cas Lek Cesk; 1996 Dec 18; 135(24):803-6. PubMed ID: 9072300
    [Abstract] [Full Text] [Related]

  • 12. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group.
    Donadio JV, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC.
    J Am Soc Nephrol; 1999 Aug 18; 10(8):1772-7. PubMed ID: 10446945
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of IgA nephropathy].
    Matousovic K, Mestecky J, Tomana M, Novak J.
    Vnitr Lek; 2008 Mar 18; 54(3):239-44. PubMed ID: 18522291
    [Abstract] [Full Text] [Related]

  • 14. IgA nephropathy: the presence of familial disease does not confer an increased risk for progression.
    Izzi C, Ravani P, Torres D, Prati E, Viola BF, Guerini S, Foramitti M, Frascà G, Amoroso A, Ghiggeri GM, Schena FP, Scolari F.
    Am J Kidney Dis; 2006 May 18; 47(5):761-9. PubMed ID: 16632014
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group.
    Hogg RJ, Lee J, Nardelli N, Julian BA, Cattran D, Waldo B, Wyatt R, Jennette JC, Sibley R, Hyland K, Fitzgibbons L, Hirschman G, Donadio JV, Holub BJ, Southwest Pediatric Nephrology Study Group.
    Clin J Am Soc Nephrol; 2006 May 18; 1(3):467-74. PubMed ID: 17699247
    [Abstract] [Full Text] [Related]

  • 17. Short-term effects of fish oil treatment on urinary excretion of high- and low-molecular weight proteins in patients with IgA nephropathy.
    Branten AJ, Klasen IS, Wetzels JF.
    Clin Nephrol; 2002 Oct 18; 58(4):267-74. PubMed ID: 12400841
    [Abstract] [Full Text] [Related]

  • 18. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.
    McIntyre CW, Fluck RJ, Lambie SH.
    Clin Nephrol; 2001 Sep 18; 56(3):193-8. PubMed ID: 11597033
    [Abstract] [Full Text] [Related]

  • 19. Mesangial C4d deposition: a new prognostic factor in IgA nephropathy.
    Espinosa M, Ortega R, Gómez-Carrasco JM, López-Rubio F, López-Andreu M, López-Oliva MO, Aljama P.
    Nephrol Dial Transplant; 2009 Mar 18; 24(3):886-91. PubMed ID: 18842673
    [Abstract] [Full Text] [Related]

  • 20. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study.
    Wakai K, Kawamura T, Endoh M, Kojima M, Tomino Y, Tamakoshi A, Ohno Y, Inaba Y, Sakai H.
    Nephrol Dial Transplant; 2006 Oct 18; 21(10):2800-8. PubMed ID: 16822793
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.